Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma Inc.

The latest announcement is out from Immix Biopharma ( ($IMMX) ). On December 7, 2025, Immix Biopharma, Inc. entered into an underwriting agreement ...

Immix Biopharma Enters Underwriting Agreement with Morgan Stanley

The latest announcement is out from Immix Biopharma ( ($IMMX) ). On December 7, 2025, Immix Biopharma announced positive results from its Phase 2 t...

Market Cap	$47.13M	P/E Ratio	N/A
52W High	$5.57	52W Low	$1.34
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	135.5%
Overall Score	68	Value Score	60
Quality Score	44	Technical Score	100

EPS Current Est	$-0.8	EPS Next Est	$-0.74
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMMX	$7.07	-4.20%	1.55M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMMX	$7.07	-4.2%	1.55M
3
4
5
6

IMMX

IMMX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Immix Biopharma Inc. Data in Excel

Get Immix Biopharma Inc. Data in Excel